<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns

PremiumRatings

2d ago

Genmab announces EC marketing authorization for TIVDAK

PremiumThe Fly

3d ago

Biotech Alert: Searches spiking for these stocks today

PremiumThe Fly

7d ago

ALLR

ALNY

PremiumThe Fly

Genmab announces Tivdak approval in Japan

7d ago

PremiumRatingsGenmab’s Promising Oncology Prospects and Strategic Growth Catalysts Highlighted in Buy Rating

16d ago

Genmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trial

The Fly

Genmab: Rina-S 120 mg/m2 led to ORR of 55.6% in Phase 2 RAINFOL trial

17d ago

Genmab’s Promising Pipeline and Strategic Focus Justify Buy Rating Despite GEN3014 Setback

Ratings

Genmab’s Promising Pipeline and Strategic Focus Justify Buy Rating Despite GEN3014 Setback

21d ago

Genmab price target lowered to DKK 2,300 from DKK 2,400 at RBC Capital

PremiumThe Fly

23d ago

Genmab price target lowered to $45 from $50 at Truist

PremiumThe Fly

23d ago

William Blair upgrades Genmab with focus now on pipeline

PremiumThe Fly

23d ago

Genmab upgraded to Outperform from Market Perform at William Blair

PremiumThe Fly

23d ago

PremiumThe FlyExpectations for J&J Genmab opt-in lowered ahead of news, says Morgan Stanley

24d ago

JPMorgan expects ‘significant’ underperformance of Genmab shares

The Fly

JPMorgan expects ‘significant’ underperformance of Genmab shares

24d ago

Genmab says J&J not exercising option on HexaBody-CD38

The Fly

Genmab says J&J not exercising option on HexaBody-CD38

24d ago

Genmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38

PremiumThe Fly

24d ago

Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment

PremiumThe Fly

1M ago

Genmab upgraded to Outperform from Market Perform at Leerink

PremiumThe Fly

2M ago

Genmab A/S Navigates Global Economic and Geopolitical Challenges Amidst Market Volatility

PremiumCompany Announcements

2M ago

PremiumThe FlyGenmab upgraded to Neutral from Underperform at Exane BNP Paribas

2M ago

The Fly

Genmab upgraded to Neutral from Underperform at Exane BNP Paribas

2M ago

NVO

Genmab A/S (0MGB) Q4 Earnings Cheat Sheet